Product News

Share this article:

UCB received FDA approval on a new indication for Cimzia, an injectable tumor necrosis factor (TNF) blocker. Cimzia is now indicated for moderate to severe rheumatoid arthritis, in addition to its prior indication for Crohn's disease. Cimzia will compete other TNF blockbusters such as Abbott's Humira, Johnson & Johnson's Remicade and Wyeth/Amgen's Enbrel.

 

Takeda received an FDA nod for an extended release version of its combo med Actoplus Met: Actoplus Met XR. Actoplus Met and Actoplus Met XR are indicated for the treatment of type 2 diabetes.

Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.